GlassScriptPhysician profile
Ritchell Villaluz
NPI 1184118101
$9,197.51
in general payments reported to CMS, 2019-2025
27 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,267 · 2022: $1,858 · 2023: $2,065 · 2024: $2,211 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,072.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,821.19 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,700.87 | 2021-2025 | |
| Novo Nordisk INC | $893.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $743.32 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $719.49 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.25 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $374.34 | 2022-2025 | |
| Lilly USA, LLC | $343.99 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $271.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $271.35 | 2021-2023 | Xarelto |
| Pfizer INC. | $246.96 | 2023-2025 | |
| Cumberland Pharmaceuticals, INC. | $219.33 | 2024-2025 | Kristalose |
| Novartis Pharmaceuticals Corporation | $156.82 | 2022-2025 | |
| Antares Pharma, INC. | $154.79 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Inspire Medical Systems, INC. | $142.88 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $138.73 | 2022 | |
| Medtronic, INC. | $109.27 | 2023 | Closurefast |
| Amarin Pharma, INC. | $90.00 | 2021 | |
| Exact Sciences Corporation | $47.26 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $44.86 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $31.34 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $29.20 | 2021 | |
| Sanofi Pasteur INC. | $22.88 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.98 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $19.86 | 2021 | |
| Allergan, INC. | $18.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.34 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritchell Villaluz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.